BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26

• Business

  ArQule, Inc. To Report Third Quarter 2014 Financial Results On November 10, 2014

  November 3, 2014

   · 

  1 min read
• Business

  Ekso Bionics Licences Intellectual Property To Ottobock

  November 3, 2014

   · 

  6 min read
• Business

  Radius Appoints Industry Veteran Dr. Willard Dere To Board Of Directors

  November 3, 2014

   · 

  2 min read
• Business

  Intact Vascular Strengthens Executive Management Team Adding Bryan A. Claseman As VP Of Marketing & Business Development And Marc Penna As VP Of Clinical Affairs

  November 3, 2014

   · 

  1 min read
• Drug Development

  Otsuka America Pharmaceutical, Inc. And H. Lundbeck A/S Release: Aripiprazole Once-Monthly Injectable Shows Superior Effectiveness To Paliperidone Palmitate Once-Monthly Injectable On Quality Of Life Scale In Patients With Schizophrenia

  November 3, 2014

   · 

  16 min read
• BioMidwest

  Medtronic, Inc. Launches Resolute Onyx™ Drug-Eluting Stent Following CE Mark

  November 3, 2014

   · 

  3 min read
• Bio NC

  Pharming Group And Salix Pharmaceuticals, Ltd. Announce The Launch Of Ruconest® In The U.S. For The Treatment Of Acute Angioedema Attacks In Patients With Hereditary Angioedema (HAE)

  November 3, 2014

   · 

  10 min read
• Drug Development

  Kolltan Pharmaceuticals Inc. Begins Phase 1b Cancer Study Evaluating KTN3379 In Combination With Multiple Targeted Therapies At Sarah Cannon Research Institute

  November 3, 2014

   · 

  3 min read
• Business

  Stentys Expands Product Offering To All Coronary Stent Indications Through Exclusive Agreement With Micell Technologies To Distribute Its Novel Drug-Eluting Stent

  November 3, 2014

   · 

  1 min read
• Drug Development

  BioLineRx Ltd. Files Protocol Amendment To Phase 2 Study For AML Treatment Based On Encouraging Efficacy And Strong Safety Profile

  November 3, 2014

   · 

  8 min read